SEC Form 4 · accession 0001320383-26-000006
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Ahlers
Officer — Chief Financial Officer
Period of report
Jul 30, 2026
Accepted (ET)
Aug 3, 2026 · 4:19 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001645460
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 30, 2026 | A | 25,500 | $0.00 | A | 25,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $30.40 | Jul 30, 2026 | A | 51,000 | A | — | Jul 30, 2036 | Common Stock | 51,000 | 51,000 | D |
Explanation of responses
- F1Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.
- F2The stock option becomes exercisable in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.